Pasithea Therapeutics Corp

Pasithea Therapeutics Corp. is a biotechnology company focuses on the research and discovery of new and treatments for psychiatric and neurological disorders. The company was founded by Yassine Bendiabdallah and Steinman Lawrence J in May, 2020 and is headquartered in Miami Beach, FL.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

-- AUD $1 million (U.S $694,000) grant transferred as part of Alpha-5 Integrin, LLC transaction ---- Provides approximately U.S. $694,000 of non-dilutive funding -- MIAMI BEACH, Fla., July 14, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a novel biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders, today announced the availability of an AUD $1 million (U.S. $694,000) drug development research award following the Company's acquisition of Alpha-5 integrin, LLC (“Alpha-5”). The grant was awarded by FightMND, the largest independent funder of amyotrophic lateral sclerosis (“ALS”)/motor neuron disease (“MND”) research in Australia.

Pasithea Therapeutics Awarded a Drug Development Research Grant

NEW YORK--(BUSINESS WIRE)--Camac Partners, LLC, affiliates of Concord Investment Partners Ltd., and Leonite Capital LLC (collectively with their affiliates, the "Investor Group" or "we"), who together are the largest stockholder of Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), today issued the following statement regarding the Company's dilutive and reactionary acquisition of Alpha-5 integrin, LLC (“Alpha-5”): “Given our group's status as Pasithea's largest stockhold

Investor Group Comments on Pasithea Therapeutics' Seemingly Defensive and Dilutive Related-Party Acquisition of Alpha-5

MIAMI BEACH, Fla., June 23, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a novel biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders, today announced that its Chief Executive Officer, Dr. Tiago Reis Marques, will participate in the H.C. Wainwright 1st Annual Mental Health Conference: Neuropsychiatry, Psychedelics and Beyond, as follows:

Pasithea Therapeutics to Participate in the H.C. Wainwright 1st Annual Mental Health Conference: Neuropsychiatry, Psychedelics and Beyond

- Alpha-5 is a potentially first-in-class monoclonal antibody for the treatment of amyotrophic lateral sclerosis (ALS) and other neurological diseases -- Expands pipeline across Pasithea's core therapeutic areas to drive enhanced growth -- Closing consideration of 3.26 million shares of Pasithea common stock -- Pasithea to hold a webcast on June 22 at 9 a.m. ET to discuss the transaction -

Pasithea Therapeutics Acquires Alpha-5 Integrin, LLC

MIAMI BEACH, Fla., April 14, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a novel biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders, today announced its Chief Executive Officer, Tiago Reis Marques, will present at NobleCon18 - Noble Capital Markets' Eighteenth Annual Investor Conference in Hollywood, FL, as follows:

Pasithea Therapeutics to Present at the NobleCon18 Investor Conference 2022

-- Cash Balance of $52.9 million to fund operations well into 2024 ---- Initiation of a drug development program in schizophrenia ---- Initiation of a drug development program in multiple sclerosis ---- Launched ketamine clinics in the U.K. and U.S. and expanded treatment options -- MIAMI BEACH, Fla., March 30, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a novel biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders, is pleased to provide a business update and summary of key accomplishments since its Initial Public Offering (“IPO”) in September 2021.

Pasithea Therapeutics Announces Financial and Business Results for the Fourth Quarter and Full Year 2021 and Business Update for 2022

Newest member is a renowned thought leader in the identification of neurobiological mechanisms of mental illness Newest member is a renowned thought leader in the identification of neurobiological mechanisms of mental illness

Pasithea Therapeutics Strengthens its Scientific Advisory Board with the Appointment of Preeminent Scientist Dr. Daniel Weinberger

Borqs Technologies

Color Star Technology

Making a penny stocks watchlist for January? Check these three out The post Hot Penny Stocks For Your January 2022 Watchlist appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Hot Penny Stocks For Your January 2022 Watchlist

Aditxt Inc

Camber Energy

Can these three penny stocks continue to make gains next month? The post Top Penny Stocks to Watch During Today's Bull Run appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Top Penny Stocks to Watch During Today's Bull Run

Pasithea Therapeutics (KTTA) stock is heading higher on heavy trading Thursday even without any recent news from the biotech company. The post KTTA Stock Alert: 6 Things to Know About Pasithea Therapeutics as Shares Soar Today appeared first on InvestorPlace.

KTTA Stock Alert: 6 Things to Know About Pasithea Therapeutics as Shares Soar Today

-- Expanding Pasithea Clinics footprint in London -- -- Expanding Pasithea Clinics footprint in London --

Pasithea Therapeutics Opens Second Ketamine Therapy Clinic in the United Kingdom

Pasithea Therapeutics Corp's (NASDAQ: KTTA) subsidiary, Pasithea Clinics, has opened its second London clinic in Marylebone, offering intravenous (IV) ketamine therapy to patients suffering from treatment-resistant mental health issues. What Happened: The Company opened its first U.K. clinic in Knightsbridge in October.

EXCLUSIVE: Pasithea Expands Its Footprint With Second Ketamine Therapy Clinic In UK

-- Pasithea Clinics commences in-home IV ketamine infusion therapy in Florida and Nevada -- -- Treatments conducted by board-certified medical professionals --

Pasithea Therapeutics Expands its Mobile Clinics into Florida and Nevada

MIAMI BEACH, Fla., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA; KTTAW) (“Pasithea” or the “Company”), a biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders, today announced the closing of its previously announced private placement of common stock and warrants priced at a premium to the market under Nasdaq rules. The Company sold an aggregate of 8.68 million shares of common stock and warrants to purchase 8.68 million shares of common stock at a purchase price of $3.50 per share and accompanying warrant for gross proceeds to the Company of $30.4 million, before deducting the placement agent's fees and other estimated offering expenses.

Pasithea Therapeutics Corp. Announces Closing of $30.4 Million Private Placement Priced at a Premium to the Market Under Nasdaq Rules

Pasithea Therapeutics Corp (NASDAQ: KTTA) shares shed their gains from yesterday after it announced a private offering of 8.68 million shares and warrants to purchase 8.68 million shares. The offer price of $3.50 per share represents a steep discount of 38% from the last close price of $5.60 that more than doubled on Tuesday.

Pasithea Stock Plunges After Equity Raise of $30M

MIAMI BEACH, Fla., Nov. 24, 2021 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA; KTTAW) (“Pasithea” or the “Company”), a biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders, today announced that it has entered into securities purchase agreements with certain institutional investors to purchase 8.68 million shares of its common stock and warrants to purchase 8.68 million shares of its common stock, at a purchase price of $3.50 per share and accompanying warrant in a private placement priced at a premium to the market under Nasdaq rules. The gross proceeds to the Company from the private placement are expected to be approximately $30.4 million before deducting the placement agent's fees and other estimated offering expenses.

Pasithea Therapeutics Corp. Announces Pricing of a $30.4 Million Private Placement Priced at a Premium to the Market Under Nasdaq Rules

The stock price of Pasithea Therapeutics Corp (NASDAQ: KTTA) increased by over 25% pre-market today. This is why it happened.

Pasithea Therapeutics (KTTA) Stock: Why The Price Jumped Today

Pasithea Therapeutics (KTTA) stock is rocketing higher on Tuesday after adding esketamine nasal spray to its U.K. offerings. The post KTTA Stock: The Depression Nasal Spray News That Has Pasithea Therapeutics Investors Ecstatic Today appeared first on InvestorPlace.

KTTA Stock: The Depression Nasal Spray News That Has Pasithea Therapeutics Investors Ecstatic Today

Shares of penny stock KTTA are on the move and here's what's going on. The post Hot Penny Stocks Today: Why Is KTTA Stock Moving?

Hot Penny Stocks Today: Why Is KTTA Stock Moving?

The stock price of Pasithea Therapeutics Corp (NASDAQ: KTTA) increased by over 135% pre-market today. This is why it happened.

Pasithea Therapeutics (KTTA) Stock: Why The Price Surged Today

Pasithea Clinics is one of only three accredited clinics in the U.K. approved to offer esketamine nasal spray (SPRAVATO®) for treatment of mental health disorders Pasithea Clinics is one of only three accredited clinics in the U.K. approved to offer esketamine nasal spray (SPRAVATO®) for treatment of mental health disorders

Pasithea Therapeutics Adds Esketamine Nasal Spray to its Clinic Offerings in the U.K.

– Pasithea Clinics commences IV ketamine infusion therapy in Knightsbridge, London, for the treatment of mental health disorders – – Pasithea Clinics commences IV ketamine infusion therapy in Knightsbridge, London, for the treatment of mental health disorders –

Pasithea Therapeutics Announces Successful Treatment of First Patients in the UK with Ketamine Infusion Therapy

-- Pasithea Clinics partners with ZEN Healthcare – a network of health clinics in Central London – to offer ketamine infusion therapy for the treatment of mental health disorders -- -- Ketamine in sub-anesthetic doses has shown to be highly effective at treating some psychiatric disorders, such as treatment-resistant depression and post-traumatic stress disorder --

Pasithea Therapeutics Opens its First Ketamine Therapy Clinic in the United Kingdom

Pasithea Therapeutics ( KTTA , Financial) ( KTTAW , Financial) caught my eye recently as an emerging biotech player with a different approach to business. On first impression, the company may seem like any other listed development-stage biotechnology player which could take years to generate any kind of revenues and which will go through a string of public issues to finance its research, resulting in constant dilution.

Pasithea Therapeutics: Revenues Just Around the Corner

Photo by CDC on Unsplash Pasithea Therapeutics ( NASDAQ: KTTA), a Florida-based biotechnology company, has teamed with life sciences company Evotec SE (OTCMKTS: EVTCY) as its research partner to help discover new compounds aimed at treating depression and schizophrenia.

News for Pasithea Therapeutics Corp Stock (KTTA)